| content | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Nateglinide
|
|
| Systematic (IUPAC) name | |
| 3-phenyl-2-(4-propan-2-ylcyclohexyl) carbonylamino-propanoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | A10 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C19H27NO3 |
| Mol. mass | 317.423 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 98% |
| Metabolism | ? |
| Half life | 1.5 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data |
, |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by the Swiss pharmaceutical company Novartis.
Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Pharmacology
Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
Dosage
Nateglinide is delivered in 60mg & 120mg tablet form.
External links
- Starlix - website of the manufacturer.
- How Nateglinide Works - website of the manufacturer.
|
||||||||||||||||||||||||||||||||||||||||||||
